Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker

Medical Hypotheses

Volumn 68, Issue 5, 2007, Pages 1096-1098

  Yamagishi, S ^a   Matsui, T ^a   Nakamura, K ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; GLYCATION END PRODUCT RECEPTOR; LOW DENSITY LIPOPROTEIN; NIFEDIPINE; PROTEIN DERIVATIVE; RECEPTOR; SENESCENT MACROPROTEIN DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; AUTOCRINE EFFECT; BLOOD VESSEL CALCIFICATION; CELL DIFFERENTIATION; CORONARY ARTERY; DIABETIC ANGIOPATHY; DISEASE ACTIVITY; ENDOTHELIUM CELL; GLYCATION; HEART INFARCTION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; OSTEOBLAST; PATHOGENESIS; PERICYTE; PLAQUE FORMING CELL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UNSTABLE ANGINA PECTORIS;

CALCINOSIS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; DIHYDROPYRIDINES; HUMANS; MODELS, BIOLOGICAL; NIFEDIPINE;

ANGINA;

EID: 33847064210     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.07.059     Document Type: Article

References (15)

1. Fitzgerald P.J., Ports T.A., and Yock P.G. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation 86 (1992) 64-70
2. Watson K.E., Bostrom K., Ravindranath R., Lam T., Norton B., and Demer L.L. TGF-β1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 93 (1994) 2106-2113
3. Tintut Y., Alfonso Z., Saini T., et al. Multilineage potential of cells from the artery wall. Circulation 108 (2003) 2505-2510
4. Yamagishi S., Nakamura K., and Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 1 (2005) 93-106
5. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Design 11 (2005) 2279-2299
6. Bierhaus A., Hofmann M.A., Ziegler R., and Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37 (1998) 586-600
7. Schmidt A.M., and Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2 (2000) 430-436
8. Okamoto T., Yamagishi S., Inagaki Y., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. Faseb J 16 (2002) 1928-1930
9. Yamagishi S., Fujimori H., Yonekura H., Tanaka N., and Yamamoto H. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Bioph Res Co 258 (1999) 353-357
10. Yamagishi S., Nakamura K., Takenaka K., Matsui T., and Inoue H. Pleiotropic effects of nifedipine on atherosclerosis. Curr Pharm Design 12 (2006) 1543-1547
11. Yamagishi S., Inagaki Y., Abe R., et al. Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha. Drug Exp Clin Res 29 (2003) 141-145
12. Yamagishi S., Inagaki Y., and Kikuchi S. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drug Exp Clin Res 29 (2003) 147-152
13. Yamagishi S., and Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drug Exp Clin Res 30 (2004) 169-175
14. Yamagishi S., Kikuchi S., Takenaka K., Nakamura K., and Takeuchi M. Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells. Drug Exp Clin Res 31 (2004) 221-226
15. Sobal G., Menzel E.J., and Sinzinger H. Calcium antagonists as inhibitors of in vitro low-density lipoprotein oxidation and glycation. Biochem Pharmacol 61 (2001) 373-379